Dott.ssa Sciamanna Marta
Linea di ricerca: Retina medica e chirurgica
Unità di ricerca: UR Retina Medica
Attività medica: Medico oftalmologo presso IRCCS Fondazione G.B. Bietti nelle sedi di Via Livenza, 3 e Via di santo Stefano Rotondo 6, presso Presidio Ospedaliero Britannico, Roma
Pubblicazioni scientifiche: PubMed
Profilo linkedin: Marta Sciamanna
- Luglio 1994 – Laurea in Medicina e Chirurgia presso L’Università Cattolica del Sacro Cuore Policlinico. A. Gemelli, Roma.
- Ottobre 1998 – Specializzazione in Oftalmologia presso l’Università degli Studi di Roma “La Sapienza”
- Dal 2008 Ricercatore linea Retina medica presso Fondazione G.B.Bietti –IRCCS via Livenza 3, 00198 Roma
- 2010-2016 Attività assistenziale presso il centro per le maculopatie della Fondazione G.B.Bietti-IRCCS presso il complesso ospedaliero S.Giovanni -Addolorata, Via di santo Stefano Rotondo 6, Roma
- SOI
- SIR
- AIMO
- MONTBLANC Study. A 12-month randomized, double-masked, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with LucentisTM versus LucentisTM monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Co-Investigator.
- DEGAS Study. A phase II prospective, randomized, multi-center, diabetic macular edema dose ranging, comparator study evaluating the efficacy and safety of PF-04523655 versus laser therapy (DEGAS). Co-investigator
- GALILEO Study. A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO). Co-Investigator.
- RETAIN study Multicentric, phase 3b, randomized, single blind, controlled, 2 years follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab treat and extend vs 0.5 mg ranibizumab as needed in patients with diabetic macular edema Co-investigator
- VIVID DME Study. A randomised, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macula edema. A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema. Co-investigator
- TREND Study A 12-month, phase IIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular age-related macular degeneration. Co-investigator
- A Phase II multicenter, randomizes, double-maskerd, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patents with geographic atrophy secondary to o age-related macular degeneration. (CHROMA) Co-investigator
- SEQUOIA study: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration Co-investigator
- AZURE study: An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD) Co-investigator
- ARIES study: Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept – a randomized, open-label, active-controlled, parallel-group phase IV/IIIb study Co-investigator
- CENTERA study: A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion Co-investigator
- KESTREL study: A two-year, three-arm, randomized,double-masked, multicenter, phase III study assessing the efficacy and safety of Brolucizumab versus Aflibercept in adult patients with visual impairment due to diabetic macular edema. Co-investigator
- PANDA study: A phase III, Multicentric, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Combercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration. Co-investigator
- APELLIS Study: A Phase III, multi-center, randomized, double masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injection in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) Co-investigator
- RAPTOR Study: An Eighteen-Month, Two -Arm, Randomized, Double-Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion.Co-investigator
- YOSEMITE study: A phase III, Multicentric, Double-Masked, Active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with ddiabetic macular edema.Co-investigator Co- investigator
- TENAYA Study: A phase III, Multicentric, Double-Masked, Active comparator-controlled study to evaluate RO6867461 in Patients with Neovascular Age-related Macular Degeneration.
- COAST Study: A Phase 3, Multicenter, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD).Co-investigator
- PULSAR study: Randomized, double-masked, active-controlled, phase 3 study of the efficacy and safety of high dose Aflibercept in patients with Neovascular age-related Macular Degeneration. Co-investigator
- LONGITUDE study: aALongitudinal, Biomarker Study Of Anti-VEGF , To Explore The Relationship Between Aqueous Humor Composition And Multimodal Imaging In Neovascular Age-Related Macular Degeneration And Diabetic Macular Edema. Co-investigator
- AVONELLE study: A multicenter, open-label extension study to evaluate the long-term safety and tollerability of Faricimab in patients with Neovasculsr Age-related Macular Degeneration Co-investigator
- Rhone-X study: A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic Macular Edema. Co-investigator
- COMINO study: A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion.Co-investigator
- IMAGINE study: One year, single arm, open label, multicenter, phase IV study using multimodal imaging to guide disease activity assessment through innovative early predictive anatomical biomarkers of fluid resolution in wAMD patients treated with brolucizumab. Co-investigator
- CHART study: Characterization of Retinal disease progression in eyes with NPDR in Diabetes Type 2 using non-trattive invasive procedures. Co-investigator
- RECOGNISED Study Retinal and cognitive disfunction in Type 2 Diabetes: unraveling the common pathways and identification of patients at risk of dementia Recognised. Co-investigator
- MACUSTAR study: development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD) Co-investigator
- Capitolo Testo High Miopia “Optical devices in highly myopic eyes” Scassa C, Sciamanna M, Gazzaniga D. 2004
- Capitolo Testo High Miopia “ OCT in differential Diagnosis of macular pathologies in high Miopia” Scassa C, Ripandelli G, Sciamanna M. 2004
